Share Price and Basic Stock Data
Last Updated: November 26, 2025, 7:34 pm
| PEG Ratio | 0.15 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fermenta Biotech Ltd operates in the pharmaceuticals sector, with its stock currently priced at ₹279 and a market capitalization of ₹820 Cr. The company has demonstrated fluctuating sales figures over the past quarters, with a notable peak of ₹156 Cr in December 2024, following a decline to ₹55 Cr in December 2022. For the fiscal year ending March 2025, the total sales stood at ₹468 Cr, a significant increase from ₹335 Cr recorded in March 2024. The trailing twelve months (TTM) sales reached ₹563 Cr, indicating strong recovery trends. However, the quarterly sales data reveals volatility, with quarterly revenues ranging from a low of ₹55 Cr to a high of ₹156 Cr, illustrating the challenges of consistent revenue generation. The operating profit margin (OPM) has also been inconsistent, peaking at 34% in December 2024 but dipping to negative figures in several quarters, reflecting operational challenges amid fluctuating sales.
Profitability and Efficiency Metrics
Fermenta Biotech’s profitability metrics depict a mixed performance. The company reported a net profit of ₹76 Cr for the fiscal year ending March 2025, a recovery from a loss of ₹24 Cr in March 2024. The profit before tax stood at ₹83 Cr, showcasing improved operational efficacy. The return on equity (ROE) is notably strong at 24.9%, while the return on capital employed (ROCE) is reported at 23%, both indicating efficient use of capital relative to earnings. However, the company has faced challenges with operating profit margins, which fluctuated from as low as 5% to as high as 34% over the past fiscal periods. The cash conversion cycle (CCC) currently stands at 189 days, indicating potential inefficiencies in managing working capital, particularly in receivables and inventory management. Despite these challenges, the strong ROE and ROCE figures suggest that Fermenta Biotech can effectively generate returns on its equity and capital employed.
Balance Sheet Strength and Financial Ratios
The balance sheet of Fermenta Biotech showcases a robust financial position, characterized by a low debt level. Total borrowings are reported as ₹0 Cr, and the long-term debt-to-equity ratio is an impressive 0.04, indicating minimal reliance on debt financing. The current ratio stands at 1.58, suggesting healthy liquidity, while the quick ratio at 0.99 indicates that the company is nearly able to cover its short-term liabilities with its liquid assets. The price-to-book value (P/BV) ratio is reported at 2.20x, which is relatively high compared to industry norms, indicating that the stock may be perceived as overvalued. The interest coverage ratio (ICR) is strong at 8.57x, demonstrating the company’s ability to meet its interest obligations comfortably. Overall, the balance sheet reflects a favorable financial health position, although the high P/BV may warrant caution among investors.
Shareholding Pattern and Investor Confidence
Fermenta Biotech’s shareholding pattern reveals significant promoter confidence, with promoters holding 64.08% of the company’s shares as of March 2025, up from 59.58% in December 2022. This increasing stake suggests a strong commitment from management towards the company’s growth trajectory, which could instill confidence among investors. However, foreign institutional investors (FIIs) hold a mere 0.02% stake, indicating limited external institutional interest. The public shareholding stands at 34.75%, reflecting a moderate level of public engagement. The number of shareholders has declined from 17,610 in December 2022 to 13,760 in March 2025, which may raise concerns about retail investor confidence. The lack of substantial institutional investment, particularly from FIIs, could be perceived as a risk factor for the stock, potentially limiting its liquidity and market interest.
Outlook, Risks, and Final Insight
The outlook for Fermenta Biotech appears cautiously optimistic, driven by its strong profitability metrics and low debt levels. However, the company faces several risks, including revenue volatility and operational inefficiencies, as reflected in the fluctuating OPM and CCC. Additionally, the declining number of shareholders and minimal institutional interest could pose challenges in attracting new investments. Strengths such as high ROE and ROCE, along with strong promoter backing, provide a solid foundation for growth. In scenarios where Fermenta can stabilize its revenue streams and improve operational efficiencies, it may see enhanced investor confidence and market performance. Conversely, continued volatility in sales and lack of institutional interest could hinder its growth potential, making it essential for the management to address these operational and market challenges effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Fermenta Biotech Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 162 Cr. | 129 | 247/84.3 | 35.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,538 Cr. | 417 | 479/192 | 94.0 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.5 Cr. | 28.3 | 29.1/17.0 | 98.8 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,356.00 Cr | 1,182.92 | 52.67 | 202.40 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 92 | 98 | 55 | 105 | 82 | 57 | 99 | 97 | 78 | 95 | 156 | 140 | 136 |
| Expenses | 87 | 95 | 65 | 86 | 72 | 71 | 74 | 92 | 77 | 76 | 103 | 103 | 108 |
| Operating Profit | 5 | 3 | -10 | 19 | 11 | -14 | 25 | 5 | 1 | 19 | 53 | 37 | 28 |
| OPM % | 5% | 3% | -18% | 18% | 13% | -24% | 25% | 6% | 1% | 20% | 34% | 26% | 21% |
| Other Income | 4 | 3 | -19 | -8 | 2 | -6 | 3 | 5 | 3 | 3 | 2 | 4 | 9 |
| Interest | 4 | 5 | 5 | 6 | 5 | 4 | 5 | 3 | 3 | 4 | 4 | 3 | 3 |
| Depreciation | 7 | 9 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Profit before tax | -2 | -8 | -41 | -1 | 2 | -29 | 16 | 1 | -6 | 12 | 45 | 32 | 28 |
| Tax % | 8% | 6% | -8% | 373% | 0% | 0% | 38% | 885% | 0% | 6% | 16% | -4% | 23% |
| Net Profit | -3 | -8 | -38 | -5 | 2 | -29 | 10 | -7 | -6 | 11 | 38 | 33 | 22 |
| EPS in Rs | -0.88 | -2.75 | -12.70 | -1.40 | 0.62 | -9.70 | 3.35 | -2.36 | -1.98 | 3.87 | 12.54 | 11.68 | 7.42 |
Last Updated: August 19, 2025, 3:45 pm
Below is a detailed analysis of the quarterly data for Fermenta Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 136.00 Cr.. The value appears to be declining and may need further review. It has decreased from 140.00 Cr. (Mar 2025) to 136.00 Cr., marking a decrease of 4.00 Cr..
- For Expenses, as of Jun 2025, the value is 108.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 103.00 Cr. (Mar 2025) to 108.00 Cr., marking an increase of 5.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 9.00 Cr..
- For OPM %, as of Jun 2025, the value is 21.00%. The value appears to be declining and may need further review. It has decreased from 26.00% (Mar 2025) to 21.00%, marking a decrease of 5.00%.
- For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 5.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 32.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 4.00 Cr..
- For Tax %, as of Jun 2025, the value is 23.00%. The value appears to be increasing, which may not be favorable. It has increased from -4.00% (Mar 2025) to 23.00%, marking an increase of 27.00%.
- For Net Profit, as of Jun 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 11.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 7.42. The value appears to be declining and may need further review. It has decreased from 11.68 (Mar 2025) to 7.42, marking a decrease of 4.26.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 139 | 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 468 | 563 |
| Expenses | 113 | 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 352 | 418 |
| Operating Profit | 26 | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 115 | 145 |
| OPM % | 19% | 11% | 13% | 7% | 31% | 39% | 23% | 22% | 16% | 5% | 8% | 25% | 26% |
| Other Income | 3 | 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | -20 | 4 | 7 | 20 |
| Interest | 5 | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 13 |
| Depreciation | 10 | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 23 |
| Profit before tax | 14 | 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 | 130 |
| Tax % | 24% | 67% | 61% | 49% | 28% | 8% | -37% | 18% | 44% | 4% | 143% | 8% | |
| Net Profit | 10 | 1 | 2 | -9 | 46 | 117 | 60 | 43 | 15 | -53 | -24 | 76 | 111 |
| EPS in Rs | 2.86 | 0.17 | -0.41 | -4.14 | 12.21 | 42.71 | 20.23 | 15.46 | 5.25 | -17.36 | -7.84 | 26.12 | 38.06 |
| Dividend Payout % | 29% | 249% | -51% | -5% | 2% | 1% | 24% | 16% | 23% | -7% | -16% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -90.00% | 100.00% | -550.00% | 611.11% | 154.35% | -48.72% | -28.33% | -65.12% | -453.33% | 54.72% | 416.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 190.00% | -650.00% | 1161.11% | -456.76% | -203.07% | 20.38% | -36.78% | -388.22% | 508.05% | 361.95% |
Fermenta Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 59% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 67% |
| 5 Years: | 7% |
| 3 Years: | 74% |
| TTM: | 532% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | -3% |
| 3 Years: | 10% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 6% |
| 3 Years: | 4% |
| Last Year: | 25% |
Last Updated: September 5, 2025, 3:30 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 91 | 101 | 99 | 83 | 59 | 87 | 66 | 80 | 44 | 76 | 74 |
| Inventory Days | 149 | 125 | 160 | 208 | 234 | 347 | 594 | 441 | 380 | 309 | 245 | 306 |
| Days Payable | 120 | 95 | 113 | 147 | 183 | 169 | 260 | 169 | 154 | 109 | 182 | 192 |
| Cash Conversion Cycle | 136 | 122 | 148 | 160 | 134 | 237 | 421 | 338 | 306 | 244 | 139 | 189 |
| Working Capital Days | 9 | -61 | -49 | 33 | 54 | 43 | 70 | 54 | 67 | -18 | 9 | 40 |
| ROCE % | 9% | 3% | 6% | 2% | 31% | 41% | 12% | 13% | 7% | -0% | 3% | 23% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 26.35 | -7.99 | -17.85 | 5.33 | 15.77 |
| Diluted EPS (Rs.) | 26.35 | -7.99 | -17.85 | 5.33 | 15.69 |
| Cash EPS (Rs.) | 34.50 | 0.24 | -8.77 | 14.08 | 21.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 124.33 | 98.76 | 108.08 | 128.76 | 124.90 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 124.33 | 98.76 | 108.08 | 128.76 | 124.90 |
| Revenue From Operations / Share (Rs.) | 160.95 | 116.25 | 121.27 | 138.15 | 130.79 |
| PBDIT / Share (Rs.) | 41.69 | 13.62 | 8.88 | 24.12 | 31.17 |
| PBIT / Share (Rs.) | 33.39 | 5.06 | -0.90 | 15.26 | 24.13 |
| PBT / Share (Rs.) | 28.53 | -3.42 | -17.98 | 9.34 | 17.90 |
| Net Profit / Share (Rs.) | 26.19 | -8.31 | -18.56 | 5.22 | 14.74 |
| NP After MI And SOA / Share (Rs.) | 26.35 | -7.99 | -17.85 | 5.35 | 15.77 |
| PBDIT Margin (%) | 25.90 | 11.71 | 7.32 | 17.46 | 23.83 |
| PBIT Margin (%) | 20.74 | 4.34 | -0.74 | 11.04 | 18.44 |
| PBT Margin (%) | 17.72 | -2.94 | -14.82 | 6.76 | 13.68 |
| Net Profit Margin (%) | 16.27 | -7.15 | -15.30 | 3.77 | 11.27 |
| NP After MI And SOA Margin (%) | 16.37 | -6.86 | -14.71 | 3.87 | 12.06 |
| Return on Networth / Equity (%) | 21.19 | -7.98 | -16.36 | 4.15 | 12.62 |
| Return on Capital Employeed (%) | 24.19 | 3.89 | -0.61 | 8.81 | 14.56 |
| Return On Assets (%) | 12.50 | -4.20 | -8.09 | 2.18 | 6.62 |
| Long Term Debt / Equity (X) | 0.04 | 0.14 | 0.26 | 0.30 | 0.30 |
| Total Debt / Equity (X) | 0.30 | 0.45 | 0.68 | 0.63 | 0.57 |
| Asset Turnover Ratio (%) | 0.80 | 0.56 | 0.52 | 0.55 | 0.57 |
| Current Ratio (X) | 1.58 | 1.40 | 1.21 | 1.52 | 1.48 |
| Quick Ratio (X) | 0.99 | 0.89 | 0.58 | 0.74 | 0.70 |
| Inventory Turnover Ratio (X) | 4.45 | 0.70 | 0.77 | 0.91 | 1.06 |
| Dividend Payout Ratio (NP) (%) | 4.69 | -15.65 | -7.00 | 46.68 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 3.57 | 217.49 | -15.50 | 17.58 | 0.00 |
| Earning Retention Ratio (%) | 95.31 | 115.65 | 107.00 | 53.32 | 0.00 |
| Cash Earning Retention Ratio (%) | 96.43 | -117.49 | 115.50 | 82.42 | 0.00 |
| Interest Coverage Ratio (X) | 8.57 | 2.31 | 1.23 | 4.07 | 5.00 |
| Interest Coverage Ratio (Post Tax) (X) | 6.38 | 0.02 | -0.20 | 1.88 | 3.37 |
| Enterprise Value (Cr.) | 831.46 | 505.89 | 464.45 | 795.24 | 883.96 |
| EV / Net Operating Revenue (X) | 1.77 | 1.51 | 1.33 | 2.00 | 2.34 |
| EV / EBITDA (X) | 6.84 | 12.87 | 18.12 | 11.43 | 9.83 |
| MarketCap / Net Operating Revenue (X) | 1.70 | 1.30 | 0.88 | 1.49 | 1.91 |
| Retention Ratios (%) | 95.30 | 115.65 | 107.00 | 53.31 | 0.00 |
| Price / BV (X) | 2.20 | 1.51 | 0.98 | 1.59 | 2.00 |
| Price / Net Operating Revenue (X) | 1.70 | 1.30 | 0.88 | 1.49 | 1.91 |
| EarningsYield | 0.09 | -0.05 | -0.16 | 0.02 | 0.06 |
After reviewing the key financial ratios for Fermenta Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For Cash EPS (Rs.), as of Mar 25, the value is 34.50. This value is within the healthy range. It has increased from 0.24 (Mar 24) to 34.50, marking an increase of 34.26.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 124.33. It has increased from 98.76 (Mar 24) to 124.33, marking an increase of 25.57.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 124.33. It has increased from 98.76 (Mar 24) to 124.33, marking an increase of 25.57.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 160.95. It has increased from 116.25 (Mar 24) to 160.95, marking an increase of 44.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 41.69. This value is within the healthy range. It has increased from 13.62 (Mar 24) to 41.69, marking an increase of 28.07.
- For PBIT / Share (Rs.), as of Mar 25, the value is 33.39. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 33.39, marking an increase of 28.33.
- For PBT / Share (Rs.), as of Mar 25, the value is 28.53. This value is within the healthy range. It has increased from -3.42 (Mar 24) to 28.53, marking an increase of 31.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 26.19. This value is within the healthy range. It has increased from -8.31 (Mar 24) to 26.19, marking an increase of 34.50.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For PBDIT Margin (%), as of Mar 25, the value is 25.90. This value is within the healthy range. It has increased from 11.71 (Mar 24) to 25.90, marking an increase of 14.19.
- For PBIT Margin (%), as of Mar 25, the value is 20.74. This value exceeds the healthy maximum of 20. It has increased from 4.34 (Mar 24) to 20.74, marking an increase of 16.40.
- For PBT Margin (%), as of Mar 25, the value is 17.72. This value is within the healthy range. It has increased from -2.94 (Mar 24) to 17.72, marking an increase of 20.66.
- For Net Profit Margin (%), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 10. It has increased from -7.15 (Mar 24) to 16.27, marking an increase of 23.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.37. This value is within the healthy range. It has increased from -6.86 (Mar 24) to 16.37, marking an increase of 23.23.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.19. This value is within the healthy range. It has increased from -7.98 (Mar 24) to 21.19, marking an increase of 29.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 24.19. This value is within the healthy range. It has increased from 3.89 (Mar 24) to 24.19, marking an increase of 20.30.
- For Return On Assets (%), as of Mar 25, the value is 12.50. This value is within the healthy range. It has increased from -4.20 (Mar 24) to 12.50, marking an increase of 16.70.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.14 (Mar 24) to 0.04, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.45 (Mar 24) to 0.30, marking a decrease of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.80. It has increased from 0.56 (Mar 24) to 0.80, marking an increase of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 1.58. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 1.58, marking an increase of 0.18.
- For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 24) to 0.99, marking an increase of 0.10.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.45. This value is within the healthy range. It has increased from 0.70 (Mar 24) to 4.45, marking an increase of 3.75.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.69. This value is below the healthy minimum of 20. It has increased from -15.65 (Mar 24) to 4.69, marking an increase of 20.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.57. This value is below the healthy minimum of 20. It has decreased from 217.49 (Mar 24) to 3.57, marking a decrease of 213.92.
- For Earning Retention Ratio (%), as of Mar 25, the value is 95.31. This value exceeds the healthy maximum of 70. It has decreased from 115.65 (Mar 24) to 95.31, marking a decrease of 20.34.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.43. This value exceeds the healthy maximum of 70. It has increased from -117.49 (Mar 24) to 96.43, marking an increase of 213.92.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 8.57, marking an increase of 6.26.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.38. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 6.38, marking an increase of 6.36.
- For Enterprise Value (Cr.), as of Mar 25, the value is 831.46. It has increased from 505.89 (Mar 24) to 831.46, marking an increase of 325.57.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.77, marking an increase of 0.26.
- For EV / EBITDA (X), as of Mar 25, the value is 6.84. This value is within the healthy range. It has decreased from 12.87 (Mar 24) to 6.84, marking a decrease of 6.03.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
- For Retention Ratios (%), as of Mar 25, the value is 95.30. This value exceeds the healthy maximum of 70. It has decreased from 115.65 (Mar 24) to 95.30, marking a decrease of 20.35.
- For Price / BV (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 2.20, marking an increase of 0.69.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
- For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.09, marking an increase of 0.14.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fermenta Biotech Ltd:
- Net Profit Margin: 16.27%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 24.19% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.19% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.99
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 7.48 (Industry average Stock P/E: 43.33)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.3
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.27%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-1501, Thane One, DIL Complex, Thane Maharashtra 400610 | info@fermentabiotech.com https://www.fermentabiotech.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradeep M Chandan | Chairman & Ind.Dire (Non-Exe) |
| Mr. Krishna Datla | Exe.Vice Chairman & Whole Time Director |
| Mr. Prashant Nagre | Managing Director |
| Mr. Satish Varma | Executive Director |
| Ms. Anupama Datla Desai | Executive Director |
| Ms. Rajeshwari Datla | Non Executive Director |
| Mr. Pramod Kasat | Ind. Non-Executive Director |
| Ms. Rajashri Ojha | Ind. Non-Executive Director |
| Mr. Ramanand Mundkur | Independent Director |